期刊
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
卷 25, 期 4, 页码 511-520出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2013.09.018
关键词
-
资金
- National Heart, Lung and Blood Institute of the National Institutes of Health [U01HL071556, U01HL072734, U01HL072735, U01HL072736, U01HL072737]
- Cordis/JohnsonJohnson
- Pfizer, Inc.
- Abbott Vascular
- Otsuka America
- AstraZeneca
- Pfizer
- Medtronic
- Cook, Inc.
Purpose: To describe the experience and results from the roll-in phase of the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study. Materials and Methods: The CORAL roll-in database was used to describe the baseline characteristics of the patients in the roll-in cohort, all of whom underwent renal artery stent placement; to evaluate CORAL site performance; to compare estimates of lesion (stenosis) severity made by site interventionalists with the central CORAL angiographic core laboratory readings; and to report outcomes after renal artery stent placement. During the roll-in phase, 239 patients (mean age, 70.2 y +/- 9.0; 49% male) underwent renal artery stent procedures. Angiographic core laboratory analysis of renal arteriograms was done, and participants were followed at 1 month and 9 months. Results: Major angiographic complications were identified in 28 (13%) subjects. Kidney function remained unchanged at the short (2-4 weeks) follow-up interval. Improvement in systolic blood pressure with use of distal embolic protection devices (n = 161) did not show any clinical benefit over nonuse of such devices (n = 78) in this small series. At 9 months, there were significantly More endpoints reported by site in subjects with bilateral renal artery stenosis (P = .01) and prior history of stroke (P = .03). Conclusions: In the roll-in phase of the CORAL study, a significant number of angiographic complications were identified. No effect was seen on estimated glomerular filtration rate after renal artery stent placement, but systolic blood pressure decreased significantly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据